



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

October 21, 2014

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Sreet, Fort
Mumbai 400 001

The Manager – Listing
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

Authorised Signatory



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/12/2014

Press Release

NATCO announces USFDA Tentative Approval for Armodafinil 50mg, 150mg, and 250mg Tablets

Hyderabad, India, October 21st, 2014

Natco Pharma Limited (NSE: NATCOPHARM, BSE: 524816) announced today that its marketing partner in the USA, Breckenridge Pharmaceutical, Inc., has received a **tentative approval** from the United States Food & Drug Administration (USFDA) for Armodafinil 50mg, 150mg, and 250mg Tablets.


Breckenridge filed the Abbreviated New Drug Application (ANDA) with a Paragraph IV certification to obtain approval to engage in the commercial manufacture, use and sale of its generic to Nuvigil® prior to expiration of the listed patents. Natco and Breckenridge have entered into a settlement regarding the ANDA with Cephalon, the terms of which are confidential. Cephalon has granted Natco and Breckenridge a license to market generic versions of the 50mg, 100 mg, 150mg, 200 mg and 250mg strengths of Nuvigil®, beginning 180-days after the initial launch of these strengths.

Cephalon (acquired by Teva in 2011) sells Armodafinil 50mg, 150mg, and 250mg Tablets under Brand name Nuvigil® in the USA market. Nuvigil® is a wakefulness promoting agent for oral administration. The market size of Nuvigil® in the USA is approximately US \$457 Million for twelve months ending August 2014, according to IMS Health.

All trademarks are the property of their respective owners.

Forwarded for favour of publication

For NATCO Pharma Limited


Rajesh Chebiyam

Vice President- Business Development & Corp Support